StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.67−1.15 (-9.73%)

Close on Nov 17, 2026Market cap $8.51BP/E –Yield –

Summit Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Summit Therapeutics's enterprise value was $12.51B on Nov 11, 2026, against $13.08B a year earlier. Over the last 5 years it ranged from $20.67M to $19.19B, with a median of $6.04B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$12.51B-2.2%
2025Dec 31, 2025$12.78B+0.9%
2024Dec 31, 2024$12.67B+680.7%
2023Dec 29, 2023$1.62B+121.1%
2022Dec 30, 2022$733.64M+302.3%
2021Dec 31, 2021$182.37M+298.8%
2020Dec 31, 2020$45.73M–
2019Dec 31, 2019-$7.68M–
2018Dec 31, 2018-$13.45M-109.9%
2017Dec 29, 2017$136.39M+34.8%
2016Dec 30, 2016$101.18M–

More Summit Therapeutics figures

See a number that looks wrong?